Lab
Group Health Plan INC.
Group Health Plan INC. was paid $11.52M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 20% of everything it billed.
33Billing provider infoGROUP HEALTH PLAN INC.
EDEN PRAIRIE, MN 55344
EDEN PRAIRIE, MN 55344
33aNPI1215048913assigned 08/31/2006
33bProvider typeClinical Medical Laboratory
28Total paid$11.52M
24GClaims802,199
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Minnesota
Rank by total paid#6 of 69
Median peer was paid$48K
This provider vs. median239×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BJORKMAN, LISA controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,808 | $907K | |
| 2019 | 131,366 | $1.71M | |
| 2020 | 89,582 | $1.62M | |
| 2021 | 132,608 | $2.70M | |
| 2022 | 94,440 | $1.51M | |
| 2023 | 110,180 | $1.40M | |
| 2024incomplete | 99,215 | $1.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 33,644 | 31,566 | $2.31M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.4% | 24,306 | 23,349 | $742K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.4% | 24,073 | 23,118 | $736K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.6% | 24,972 | 23,384 | $533K |
| 86481 | 4.1% | 4,998 | 4,874 | $467K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.0% | 21,221 | 20,829 | $463K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.5% | 35,909 | 35,105 | $408K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.4% | 7,343 | 7,007 | $388K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.0% | 53,696 | 52,761 | $344K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.8% | 14,935 | 14,658 | $318K |
| 80061 | Lipid panel | 2.4% | 33,082 | 32,460 | $272K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 44,032 | 41,647 | $220K |
157 more codes
| 86780 | 1.8% | 17,498 | $209K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.8% | 6,890 | $209K |
| 86803 | 1.5% | 12,477 | $169K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 20,064 | $145K |
| 82728 | 1.2% | 13,855 | $143K | |
| 87340 | <1% | 11,800 | $112K | |
| 82607 | <1% | 10,083 | $108K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,253 | $108K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,701 | $105K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 5,448 | $97K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,489 | $95K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,067 | $91K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 581 | $78K |
| 84466 | <1% | 6,974 | $72K | |
| 88142 | <1% | 4,366 | $71K | |
| 86706 | <1% | 6,773 | $71K | |
| 86480 | <1% | 1,425 | $68K | |
| 83655 | <1% | 3,670 | $68K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,836 | $65K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,990 | $63K |
| 87536 | <1% | 1,114 | $63K | |
| 81513 | <1% | 444 | $63K | |
| 86762 | <1% | 4,562 | $62K | |
| 87481 | <1% | 1,908 | $61K | |
| 84460 | <1% | 18,635 | $59K | |
| 82570 | <1% | 17,572 | $56K | |
| 86003 | <1% | 4,382 | $55K | |
| 82565 | <1% | 18,661 | $54K | |
| 86704 | <1% | 4,526 | $52K | |
| 84702 | <1% | 3,604 | $50K | |
| 85027 | <1% | 13,005 | $50K | |
| 87088 | <1% | 7,759 | $49K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 643 | $49K |
| 80076 | <1% | 10,808 | $47K | |
| 82274 | <1% | 3,073 | $47K | |
| 83970 | <1% | 2,076 | $47K | |
| 82248 | <1% | 13,191 | $45K | |
| 86787 | <1% | 3,359 | $44K | |
| 82043 | <1% | 12,661 | $44K | |
| 86850 | <1% | 5,146 | $43K | |
| 84439 | <1% | 6,275 | $42K | |
| 83540 | <1% | 8,652 | $41K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,300 | $41K |
| 86708 | <1% | 3,120 | $39K | |
| 84450 | <1% | 12,837 | $38K | |
| 87077 | <1% | 6,113 | $36K | |
| 86140 | <1% | 10,492 | $36K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 3,242 | $33K |
| 87070 | <1% | 4,447 | $32K | |
| 87338 | <1% | 2,591 | $31K | |
| 83735 | <1% | 7,414 | $31K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 236 | $31K |
| 86317 | <1% | 2,483 | $30K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,235 | $29K |
| 87186 | <1% | 4,773 | $28K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 158 | $21K |
| 82105 | <1% | 1,502 | $21K | |
| 84146 | <1% | 1,355 | $21K | |
| 87517 | <1% | 658 | $20K | |
| 87209 | <1% | 1,152 | $19K | |
| 83516 | <1% | 1,868 | $19K | |
| 83001 | <1% | 1,201 | $18K | |
| 84403 | <1% | 911 | $17K | |
| 82784 | <1% | 1,865 | $17K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,307 | $15K |
| 82247 | <1% | 3,875 | $14K | |
| 84481 | <1% | 1,071 | $13K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 400 | $13K |
| 86900 | <1% | 4,731 | $13K | |
| 86901 | <1% | 4,680 | $13K | |
| 83718 | <1% | 1,947 | $12K | |
| 84132 | <1% | 5,081 | $12K | |
| 82950 | <1% | 2,843 | $12K | |
| 82746 | <1% | 1,023 | $11K | |
| 82670 | <1% | 516 | $11K | |
| 82947 | <1% | 4,308 | $11K | |
| 86360 | <1% | 350 | $11K | |
| 80050 | General health panel | <1% | 219 | $11K |
| 83690 | <1% | 1,888 | $10K | |
| 87177 | <1% | 1,441 | $10K | |
| 83721 | <1% | 1,557 | $10K | |
| 85652 | <1% | 6,034 | $10K | |
| 83020 | <1% | 755 | $9K | |
| 84270 | <1% | 632 | $9K | |
| 83880 | <1% | 353 | $9K | |
| 86359 | <1% | 348 | $9K | |
| 84156 | <1% | 3,133 | $9K | |
| 85018 | <1% | 4,799 | $8K | |
| 85049 | <1% | 2,303 | $8K | |
| 82465 | <1% | 2,299 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 201 | $8K |
| 82550 | <1% | 1,578 | $7K | |
| 87480 | <1% | 575 | $7K | |
| 87660 | <1% | 574 | $7K | |
| 87510 | <1% | 574 | $7K | |
| 86039 | <1% | 732 | $7K | |
| 84295 | <1% | 2,804 | $6K | |
| 86235 | <1% | 253 | $6K | |
| 84153 | <1% | 575 | $6K | |
| 84550 | <1% | 1,974 | $6K | |
| 87081 | <1% | 1,879 | $6K | |
| 87634 | <1% | 93 | $6K | |
| 86160 | <1% | 724 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 403 | $4K |
| 84520 | <1% | 1,637 | $4K | |
| 87205 | <1% | 1,143 | $4K | |
| 80164 | <1% | 908 | $4K | |
| 82951 | <1% | 304 | $3K | |
| 82681 | <1% | 125 | $3K | |
| 81001 | <1% | 1,345 | $3K | |
| 80069 | <1% | 531 | $3K | |
| 86038 | <1% | 381 | $3K | |
| 87506 | <1% | 108 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 98 | $3K |
| 85610 | <1% | 848 | $3K | |
| 83002 | <1% | 156 | $3K | |
| 86618 | <1% | 224 | $3K | |
| 82310 | <1% | 799 | $3K | |
| 86431 | <1% | 579 | $2K | |
| 84100 | <1% | 838 | $2K | |
| 86200 | <1% | 206 | $2K | |
| 87631 | <1% | 16 | $2K | |
| 86376 | <1% | 146 | $2K | |
| 85730 | <1% | 298 | $2K | |
| 87529 | <1% | 25 | $1K | |
| 86225 | <1% | 171 | $1K | |
| 84165 | <1% | 165 | $1K | |
| 82040 | <1% | 355 | $928.67 | |
| 86696 | <1% | 53 | $924.32 | |
| 83520 | <1% | 188 | $847.52 | |
| 82627 | <1% | 39 | $844.54 | |
| 86147 | <1% | 25 | $798.88 | |
| 80178 | <1% | 192 | $749.16 | |
| 86765 | <1% | 46 | $694.79 | |
| 87563 | <1% | 26 | $685.42 | |
| 86695 | <1% | 52 | $616.94 | |
| 81025 | <1% | 100 | $584.14 | |
| 80177 | <1% | 74 | $551.02 | |
| 80074 | <1% | 13 | $543.33 | |
| 82533 | <1% | 46 | $499.73 | |
| 87493 | <1% | 30 | $454.17 | |
| 87147 | <1% | 233 | $394.51 | |
| 84155 | <1% | 167 | $339.94 | |
| 84075 | <1% | 125 | $338.00 | |
| 86341 | <1% | 24 | $285.74 | |
| 80051 | <1% | 75 | $273.95 | |
| 85045 | <1% | 66 | $243.56 | |
| 82150 | <1% | 59 | $189.16 | |
| 80175 | <1% | 29 | $177.60 | |
| 82785 | <1% | 12 | $170.90 | |
| 82952 | <1% | 67 | $167.02 | |
| 83993 | <1% | 12 | $160.24 | |
| 82610 | <1% | 14 | $117.21 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 286 | $50.00 |
| 87184 | <1% | 12 | $40.89 | |
| X5622 | 0% | 365 | $0.00 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 71 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBJORKMAN, LISA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Group Health Plan, INC. | Minneapolis, MN | $204.32M |
| Group Health Plan INC. | Minneapolis, MN | $14.79M |
| Group Health Plan INC | Andover, MN | $12.93M |
| Group Health Plan INC | Saint Paul, MN | $5.57M |
| Group Health Plan, INC | Stillwater, MN | $3.65M |
| Group Health Plan INC | Saint Paul, MN | $3.61M |
| Group Health Plan INC | Saint Paul, MN | $1.16M |
| Physicians Neck & Back Clinics | Roseville, MN | $859K |
| Group Health Plan INC | Minneapolis, MN | $828K |
| Group Health Plan, INC. | Saint Paul, MN | $779K |
| Group Health Plan INC | Bloomington, MN | $594K |
| Lakeview Memorial Hospital Association INC | Stillwater, MN | $159K |
| Group Health Plan, INC. | Anoka, MN | $84K |
| Group Health Plan INC | Somerset, WI | $80K |
| Group Health Plan INC | Hudson, WI | $53K |
| Group Health Plan, INC | Stillwater, MN | $50K |
| Group Health Plan, INC | Maplewood, MN | $17K |
| Group Health Plan INC | Saint Paul, MN | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.